论文部分内容阅读
多发性硬化(MS)是中枢神经系统的脱髓鞘疾病,其临床表现多样,以起病后复发缓解交替为特征。组织病理学检查发现MS脱髓鞘班块中以活化的T细胞、巨噬细胞和数量不等的少突胶质细胞占优势,揭示MS是一免疫介导性疾病。进一步证实,MS是由T细胞介导的自身免疫性疾病,由此临床一直使用各种免疫调节剂治疗。IFN-β为目前最典型、使用最广泛的治疗剂,但治疗效果仍不肯定。本文就IFN-β在MS中治疗机制及与IL-12相互作用
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and its clinical manifestations are diverse, characterized by alternating relapsing and remission after onset. Histopathological examination revealed predominance of activated T cells, macrophages, and varying numbers of oligodendrocytes in MS demyelinating patches, revealing that MS is an immune-mediated disease. It is further confirmed that MS is an autoimmune disease mediated by T cells, whereby various immunomodulatory agents have been used clinically. IFN-β is currently the most typical and widely used therapeutic agent, but the therapeutic effect remains uncertain. This article IFN-β in the treatment of MS mechanism and IL-12 interaction